tradingkey.logo

Aardvark Therapeutics Announces FDA Alignment On Protocol Amendment Expanding Phase 3 Hero Trial Population For Prader-Willi Syndrome

ReutersOct 8, 2025 12:16 PM

- Aardvark Therapeutics Inc AARD.O:

  • AARDVARK THERAPEUTICS ANNOUNCES FDA ALIGNMENT ON PROTOCOL AMENDMENT EXPANDING PHASE 3 HERO TRIAL POPULATION FOR PRADER-WILLI SYNDROME

  • AARDVARK THERAPEUTICS ANNOUNCES FDA ALIGNMENT ON PROTOCOL AMENDMENT EXPANDING PHASE 3 HERO TRIAL POPULATION FOR PRADER-WILLI SYNDROME

  • AARDVARK THERAPEUTICS INC - TRIAL ELIGIBILITY AGE CHANGED FROM 13 TO 10 YEARS

  • AARDVARK THERAPEUTICS INC - TOPLINE DATA READOUT FOR TRIAL EXPECTED IN Q3 2026

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI